Tag: GlobeNewswire

CALGARY, Alberta, Oct. 02, 2026 (GLOBE NEWSWIRE) — Jura Energy Corporation (“Jura” or the “Company”) provides an update regarding the proceedings before the High Court of Justice of England and Wales in connection with the enforcement of arbitral awards obtained by Jura’s wholly-owned subsidiaries, Frontier Holdings Limited (“FHL”) and Spud Energy Pty Limited (“Spud”), against Petroleum Exploration (Private) Limited (“PEL”).

As previously announced on July 2, 2026, the English High Court had granted an interim freezing injunction restraining PEL from disposing of or diminishing the value of certain assets in England and Wales, up to approximately US$6.96 million, pending a return hearing.

Following the return hearing, the Court declined to continue the domestic freezing injunction, concluding that FHL and Spud had not established the required real risk of dissipation of assets. The Court also ordered FHL and Spud to pay costs to a third party involved in the proceedings in the amount of GBP 125,000 and costs to PEL in the amount of GBP 145,000. The costs award to PEL was, however, made contingent on PEL having paid its amounts due under the arbitral awards made in favour of FHL and Spud.

FHL and Spud will continue to pursue enforcement of the arbitral awards and will provide further updates to shareholders as material developments occur.

About Jura Energy Corporation

Jura is an international energy company engaged in the exploration, development and production of petroleum and natural gas properties in Pakistan. Jura is based in Calgary, Alberta, and listed on the TSX-V trading under the symbol JEC. Jura conducts its business in Pakistan through its subsidiaries, Frontier Holdings Limited and Spud Energy Pty Limited.

Forward Looking Advisory

This press release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws. The words “will”, and similar expressions are used to identify forward looking information. Specific forward-looking statements in this press release include information concerning the Jura subsidiaries’ intention to continue to seek enforcement of the arbitral awards.

The forward-looking statements contained in this press release are based on management’s beliefs, estimates and opinions on the date the statements are made in light of management’s experience, current conditions and expected future development in the areas in which Jura is currently active and other factors management believes are appropriate in the circumstances. Jura undertakes no obligation to update publicly or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise, unless required by applicable law.

Readers are cautioned not to place undue reliance on forward-looking information. By their nature, forward-looking statements are subject to numerous assumptions, risks and uncertainties that contribute to the possibility that the predicted outcome will not occur, including some of which are beyond Jura’s control. These assumptions and risks include but are not limited to risks relating to the Jura subsidiaries’ ability to successfully enforce the arbitral awards. There can be no assurance that forward-looking statements will prove to be accurate as actual results and future events could vary or differ materially from those anticipated in such statements. See Jura’s Management’s Discussion and Analysis for the year ended December 31, 2025, available on SEDAR+ at www.sedarplus.ca, for further description of the risks and uncertainties associated with Jura’s business.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Stephen Smith, Chairman, Jura Energy Corporation        
T: +44 7834 834 976
E-Mail: info@juraenergy.com
Website: www.juraenergy.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

HANGZHOU, China, Oct. 01, 2026 (GLOBE NEWSWIRE) — Geely Automobile Holdings Limited (0175.HK) reported sales of 292,168 vehicles in September, its highest monthly volume so far this year and the seventh consecutive month of both year-on-year and month-on-month growth. Sales increased 7% from a year earlier and 8% from August.

New energy vehicle sales of Geely Auto Group reached a record 190,868 units in September, up 16% year on year and accounting for 65% of total sales.

For the first nine months of 2026, Geely Auto Group sold 2,235,481 vehicles, a record for the January-September period. New energy vehicle sales reached 1,326,364 units over the same period, up 14%.

Zeekr delivered 37,216 vehicles in September, an increase of 104% year on year. Lynk & Co recorded sales of 18,493 vehicles, with new energy vehicle sales reaching 17,039 units. The Geely brand sold 236,459 vehicles during the month, and Geely NEV sales reached a new monthly record of 130,479 units.

Geely Auto Group continued to expand its international business. Sales outside of China reached 106,685 vehicles in September, up 162% year on year and exceeding 100,000 units for the fourth consecutive month. New energy vehicle exports rose 403% year on year to 73,664 units, representing 69% of September overseas sales.

For the first nine months of the year, overseas sales reached a record 797,670 vehicles, an increase of 169% from the same period last year. New energy vehicle exports grew 531% to 484,086 units and accounted for 61% of total overseas sales, a significant increase from a year earlier.

Brands and core models of Geely Auto Group continued to strengthen their presence across a number of international markets.

Zeekr began large-scale shipments of the Zeekr 9X to the UAE, while the Zeekr 009 remained the best-selling battery electric MPV in Thailand and Malaysia for multiple months.

Lynk & Co continued to expand in premium segments. In August, the brand ranked first in Ecuador’s premium vehicle market and third among PHEV SUV brands in Tunisia.

The Geely brand recorded sales of more than 4,500 vehicles in Australia in August. Cumulative sales also exceeded 36,000 vehicles in Brazil and 10,000 vehicles in the UK.

About Geely Auto Group

Geely Auto Group is a leading global automotive company headquartered in Hangzhou, China. Part of Zhejiang Geely Holding Group, Geely Auto Group develops and manufactures passenger vehicles under the Geely, Lynk & Co, and Zeekr brands.

With a strong focus on technology innovation, electrification, and sustainable mobility, Geely Auto Group operates world-class R&D centers and manufacturing facilities across China, Europe, and key international markets. The Group is committed to delivering safe, high-quality, and intelligent vehicles enabled by advanced technologies such as hybrid powertrains, full-electric architectures, smart connectivity, and autonomous driving systems.

As a global company, Geely Auto Group continues to expand its international presence through strategic partnerships, localized operations, and industry-leading platforms. Geely strives to create mobility solutions that are greener, smarter, and more accessible, driving forward the future of sustainable transportation.

Media Contact
Company: Geely Automobile Holdings (HangZhou) Co.Ltd
Contact Person: Geely Auto Group Media Relations Janet Chen
Email: media@geely.com
Website: global.geely.com

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index^® (NDX^®) replacing Warner Bros. Discovery, Inc. (Nasdaq: WBD) prior to market open on Friday, October 9, 2026.

For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/

About Nasdaq Global Indexes

Nasdaq Global Indexes is one of the world’s leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Index^® — which measures the performance of 100 of the largest Nasdaq-listed non-financial companies — is tracked by more than 200 investment products with over $800 billion in assets under management globally. Nasdaq Global Indexes publishes and maintains more than 10,000 indexes across asset classes and geographies.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Nasdaq^®, Nasdaq-100 Index^® and NDX^® are registered trademarks of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

Media Contact
Maximilian Leitenberger
Maximilian.leitenberger@nasdaq.com

Issuer & Investor Contact
Index Client Services
Indexservices@nasdaq.com

-NDAQF-

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC 

After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced the initiation of a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations under the FDA’s Real-Time Oncology Review (RTOR) program.

The RTOR program allows sponsors to submit clinical data in advance of the complete application to facilitate earlier review of efficacy and safety results. Completion of the NDA submission is expected by year-end 2026.

The NDA submission is based on data from the Phase 3 REZILIENT3 trial, which met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival for zipalertinib plus chemotherapy compared to chemotherapy alone. These results were recently presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC) during a Presidential Symposium, where potentially practice-changing clinical data are highlighted.

Zipalertinib holds FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic EGFR ex20ins NSCLC who have previously received platinum-based chemotherapy. An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.

Cullinan Therapeutics is eligible to receive $30 million and $100 million in milestone payments upon second-line and first-line U.S. regulatory approvals, respectively.

About Zipalertinib

Zipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib is investigational and has not been approved by any health authority.

Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.

About EGFR Exon 20 Insertion Mutations

NSCLC is a common form of lung cancer and up to 4% of all cases globally have EGFR ex20ins.¹ In the United States, approximately 16% of patients with NSCLC harbor EGFR mutations,¹ with insertions at exon 20 accounting for up to 12% of these mutations.²

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

 Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding the clinical development of zipalertinib, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, the potential of zipalertinib to become a first-line treatment option, the anticipated timing of the completion of the NDA submission under the RTOR program and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of clinical trial data and regulatory submissions; the risk that any NDAs, INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not accepted or cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will not be predictive of future results in connection with future studies or clinical trials; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Investors  
Nick Smith  
+1 401.241.3516  
nsmith@cullinantx.com

Media 

Rose Weldon  
+1 215.801.7644   
rweldon@cullinantx.com

References

1. Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLOS ONE. 2021;16(3): e0247620. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247620.
2. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology. 2018 Jul 5;13(10):1560–1568. Available at: https://www.jto.org/article/S1556-0864(18)30770-6/pdf.

TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”).

Medicenna is pleased to announce that all of the nominees listed in its management information circular dated August 19, 2026 (the “Circular”), were elected as directors. Each director was elected with greater than 97% of the votes cast for by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:

Nominee	Votes For	% of Votes For	Votes Against	% of Votes Against
Mr. Albert Beraldo	27,751,517	97.42%	736,191	2.58%
Mr. Richard Sutin	27,779,927	97.52%	707,781	2.48%
Mr. Angelos Georgakis	27,779,495	97.51%	708,213	2.49%
Dr. Fahar Merchant	27,715,844	97.29%	771,864	2.71%

Medicenna shareholders also approved the re-appointment of MNP LLP as auditor of the Company.

Finally, the shareholders approved the special resolution authorizing the consolidation of the Company’s issued and outstanding common shares (the “Share Consolidation”) at a ratio to be determined by the Company’s board of directors (the “Board”), within the range of one post-consolidation share for every 2 to 20 pre-consolidation shares and subject to the Board’s authority to decide not to proceed with the Share Consolidation. The Share Consolidation may be undertaken as part of Medicenna’s evaluation of available strategic opportunities, including, if appropriate, to support compliance with the listing requirements of a major U.S. stock exchange.

If implemented, the Share Consolidation could, among other things, increase the trading price per common share and support compliance with a major U.S. stock exchange’s minimum bid price requirements, if determined to be desired, and potentially enhance the Company’s ability to attract U.S. institutional investors and other investors subject to minimum share-price requirements.

If and when the Board determines to proceed with the Share Consolidation, the Company will announce the applicable consolidation ratio and effective date, subject to receipt of all required regulatory approvals.

To the extent Medicenna pursues a U.S. stock exchange listing for its common shares, the Share Consolidation is not a guarantee that Medicenna will satisfy all major U.S. stock exchange listing requirements or that its common shares will be accepted for listing. Any major U.S. stock exchange listing remains subject to the Company satisfying all applicable listing requirements and receiving approval from the major U.S. stock exchange.

A total of 31.82% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.

Please refer to the Circular available on SEDAR+ at www.sedarplus.ca for more information on the business transacted at the Meeting. A report on voting results will also be filed on SEDAR+.

About Medicenna Therapeutics

Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe. Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signaling, using its proprietary BiSKIT and T-MASK platforms.

For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the Share Consolidation, the possibility of the Company pursuing a U.S. stock exchange listing for its common shares, the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.

Investor/Company Contact
Daniel Scarr
Director, Corporate Development
Medicenna Therapeutics
ir@medicenna.com

MONTERREY, Mexico, Oct. 01, 2026 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) is pleased to invite you to participate in its Third Quarter Conference Call that will be held on:

Wednesday, October 28, 2026
11:00 AM Eastern Time
(9:00 AM Mexico City Time)

To participate in the conference call please register at the following link:

Registration: FEMSA Conference Call | 3Q26

The quarterly results will be released on October 28 before markets open.

The conference call will be live through our Zoom link. For registration, please visit https://bit.ly/FEMSA_3Q26

If you are unable to participate live, the conference call replay will be available on http://ir.femsa.com/results.cfm

About FEMSA
FEMSA is a company that creates economic and social value through companies and institutions and strives to be the best employer and neighbor to the communities in which it operates. It participates in two core sectors, retail and beverages. In retail, FEMSA is present through four divisions: i) OXXO Mexico, operating the largest small-format store chain in Mexico; ii) Americas & Mobility, which includes its OXXO convenience store operations across Latin America and the United States, as well as its gas station business in Mexico and the United States; iii) FEMSA Europe, operating convenience and foodvenience formats in five European countries; and iv) FEMSA Health, which includes drugstores and related activities in four Latin American countries. In Mexico, OXXO’s operations are enhanced by, and comprise a customer-focused ecosystem with Spin, a digital platform that leverages the OXXO store network to provide Mexican consumers with access to digital financial services, including Spin by OXXO and Spin Premia, among other initiatives. In the beverage sector, FEMSA participates through Coca-Cola FEMSA, the largest franchise bottler of Coca-Cola products in the world by volume. Across its business units, FEMSA has more than 369,000 employees in 18 countries. FEMSA is a member of the Dow Jones Best-in-Class World Index & Dow Jones Best-in-Class MILA Pacific Alliance Index, both from S&P Global; FTSE4Good Emerging Index; MSCI EM Latin America ESG Leaders Index; S&P/BMV Total México ESG, among other indexes.

CONTACT: Investor Contact
(52) 818-328-6000
investor@femsa.com
femsa.gcs-web.com

Media Contact
(52) 555-249-6843
comunicacion@femsa.com
femsa.com

TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCID: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) has entered into an agreement with Community Carbon and UpEnergy Group (collectively, the “UPE Parties”) pursuant to which the Company will receive total consideration of US$6.0 million in connection with the termination of the Community Carbon Stream and transfer of the Company’s remaining portfolio of carbon credits, with a portion of the consideration funded through the sale of certain CORSIA-tagged Tanzanian cookstove carbon credits to a third-party purchaser.

The US$6.0 million total consideration is composed of the following: (i) US$2.35 million of proceeds from the Company’s sale of certain CORSIA-tagged Tanzanian cookstove carbon credits to a third-party purchaser; (ii) US$1.47 million of proceeds from the UPE Parties’ sale of certain CORSIA-tagged Tanzanian cookstove carbon credits to a third-party purchaser, with such proceeds to be deposited by the UPE Parties into escrow and paid to the Company; (iii) US$2.18 million deposited by the UPE Parties into escrow and to be paid to the Company.

Release of the escrowed funds to the Company remains subject to the conditions set out in the agreement, including confirmation by the escrow agent that it holds the full escrow amount. To date, the Company has received US$2.35 million from the Company’s sale of certain CORSIA-tagged Tanzanian cookstove carbon credits, with the remaining US$3.65 million to be paid from the escrow account. The transaction is expected to fully close and the Company expects to have received the full US$6.0 million within ten (10) business days subject to satisfaction of the closing conditions described above.

Subject to and following release of the escrowed funds to the Company, the Company will transfer its remaining inventory of carbon credits under the Community Carbon Stream and the stream will be terminated, and the parties will grant mutual releases of all future obligations between them.

Marin Katusa, CEO, stated, “The previously announced transaction with UPE failed due to a financing by UPE not closing. The Company continued to work with the management from UPE and together we created a more complicated, but ultimately better transaction for the Company for two reasons. The first being the Company receives the full US$6 million upfront rather than over 12 months in the previously announced transaction. The second being elimination of all financing and credit pricing risk for the Company. The current carbon credit market continues to be challenging. For example, CORSIA-tagged credits have been liquid and selling for above US$8 per credit, while non-CORSIA-tagged credits in the portfolio have seen limited to no buyer interest over the last 12 months. This Agreement monetizes the current value of the Community Carbon Stream and the inventory of carbon credits by selling for a total consideration of US$6.0 million and receiving the entire amount upfront.

The Company will continue to focus our resources on maximizing value for shareholders in our existing portfolio and fully pursue the recovering of assets through ongoing litigation.

In line with this commitment to shareholders, we have filed a statement of claim against certain former executives, board members, consultants, and associated entities to hold the defendants accountable for actions that have caused financial harm to the Company, as outlined in the lawsuit. While certain defendants have filed counterclaims, we believe these to be without merit and have filed a defence to these counterclaims to vigorously defend our position.

The Company will continue to evaluate acquisitions, divestments, corporate transactions, financings, and other strategic partnership opportunities that will result in maximizing shareholder value.”

About Carbon Streaming

Carbon Streaming’s focus is to maximize value for its shareholders by optimizing its current portfolio of projects.

ON BEHALF OF THE COMPANY:
Marin Katusa, Chief Executive Officer
Tel: 365.607.6095
info@carbonstreaming.com
www.carbonstreaming.com

Investor Relations
investors@carbonstreaming.com

Media
media@carbonstreaming.com

Cautionary Statement Regarding Forward-Looking Information

This news release contains certain forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future, are forward-looking information, including, without limitation, statements regarding maximizing its existing portfolio and cash resources; statements regarding the evaluation of strategic options; statements with respect to maximizing value for its shareholders; statements regarding the Company holding certain former executives, directors, consultants, and associated entities to account and the merits of the counterclaims from certain of the defendants and the Company’s defences; statements with respect to the timing of closing of the transaction and statements with respect to receipt of the remaining US$3.65 million; transfer of the Company’s remaining portfolio of carbon credits, granting of the mutual releases and the termination of the Community Carbon Stream.

When used in this news release, words such as “estimates”, “expects”, “plans”, “anticipates”, “will”, “believes”, “intends”, “should”, “could”, “may” and other similar terminology are intended to identify such forward-looking information. This forward-looking information is based on the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking information is subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking information, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. They should not be read as a guarantee of future performance or results, and will not necessarily be an accurate indication of whether or not such results will be achieved. Factors that could cause actual results or events to differ materially from current expectations include, among other things: the closing may not occur at all or may not occur within the timeframe anticipated; the UPE Parties may fail to deposit the full escrow amount; general economic, market and business conditions and global financial conditions, including fluctuations in interest rates, foreign exchange rates and stock market volatility; volatility in prices of carbon credits and demand for carbon credits; change in social or political views towards climate change, carbon credits and environmental, social and governance initiatives and subsequent changes in corporate or government policies or regulations and associated changes in demand for carbon credits; the Company’s expectations and plans with respect to current litigation, arbitration and regulatory proceedings; reputational risk; concentration risk; inaccurate estimates of project value, which may impact the ability of the Company to execute on its growth and diversification strategy; limited operating history for the Company’s current strategy; dependence upon key management; impact of the corporate restructurings and the strategic initiatives advanced by the Company; impact of any strategic opportunities; the inability of the Company to optimize cash flows or sufficiently reduce operating expenses; risks arising from competition and future acquisition activities failure or timing delays for projects to be registered, validated and ultimately developed and for emission reductions or removals to be verified and carbon credits issued (and other risks associated with carbon credits standards and registries); foreign operations and political risks including actions by governmental authorities, including changes in or to government regulation, taxation and carbon pricing initiatives; uncertainties and ongoing market developments surrounding the validation and verification requirements of the voluntary and/or compliance markets; due diligence risks, including failure of third parties’ reviews, reports and projections to be accurate; dependence on project partners, operators and owners, including failure by such counterparties to make payments or perform their operational or other obligations to the Company in compliance with the terms of contractual arrangements between the Company and such counterparties; failure of projects to generate carbon credits, or natural disasters such as flood or fire which could have a material adverse effect on the ability of any project to generate carbon credits; volatility in the market price of the Company’s common shares or warrants; the effect that the issuance of additional securities by the Company could have on the market price of the Company’s common shares or warrants; global health crises, such as pandemics and epidemics; and the other risks disclosed under the heading “Risk Factors” and elsewhere in the Company’s Annual Information Form dated as of March 30, 2026 filed on SEDAR+ at www.sedarplus.ca.

Any forward-looking information speaks only as of the date of this news release. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise.

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) (the “Company” or “Hypercharge”), a leading EV charging operator, is pleased to announce, further to its news releases dated September 11 and September 28, 2026, that it has completed its previously announced acquisition of 100% of the equity interests of REVS Charging LLC (“REVS“) (the “Transaction”) following receipt of the acceptance of the TSX Venture Exchange (the “TSXV“). In connection with the closing of the Transaction, the Company has issued REVS, 18,000,000 common shares (the “Closing Shares”), subject to a six-month voluntary lockup (the “Lockup”).

All securities issued in connection with the foregoing, including the Closing Shares, are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws, and remain subject to the approval of the TSXV.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the 1933 Act and applicable state securities requirements or pursuant to exemptions therefrom. This news release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

About REVS
Refuel Electric Vehicle Solutions (REVS) is a full-service electric vehicle (EV) charging company providing turnkey Level 2 charging solutions for multifamily, condominium, hospitality, and commercial properties across the United States. With deep expertise in commercial real estate and EV infrastructure, REVS helps property owners, managers, and developers plan, finance, install, operate, and manage charging stations, including opportunities for deployment with no upfront capital investment. Learn more: https://www.refuelevs.com/.

About Hypercharge
Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) is a leading provider of smart electric vehicle (EV) charging solutions for residential and commercial buildings, fleet operations, and other rapidly growing sectors. Driven by its mission to accelerate EV adoption and enable the shift towards a carbon neutral economy, Hypercharge is committed to offering seamless, simple solutions, including industry-leading hardware, innovative and integrated software, and comprehensive services, backed by a robust network of public and private charging stations. Learn more: https://hypercharge.com/.

On behalf of the Company,
Hypercharge Networks Corp.
David Bibby, President & CEO

Contact
Media & Investor Relations:
Kyle Kingsnorth, Head of Marketing
kyle.kingsnorth@hypercharge.com | +1 (888) 320-2633

Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “could”, “should”, “anticipate”, “will”, “estimates”, “believes”, “intends”, “expects” and similar expressions which are intended to identify forward-looking statements. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements contained in this news release are made as of the date of this news release, and are expressly qualified by the foregoing cautionary statement. Except as expressly required by applicable securities law, the Company undertakes no obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Exodus Checkout, a new merchant payments product for accepting stablecoins, launches in Argentina and expands across Latin America

OMAHA, Neb., Oct. 01, 2026 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”) today launched Exodus Checkout, a new merchant payments solution that enables businesses to accept dollar stablecoins. Exodus is debuting Exodus Checkout through a partnership with DGO, DIRECTV’s streaming platform in Latin America, where eligible customers can now pay for their subscriptions with digital dollars.

The Exodus Checkout launch further expands Exodus’ business from allowing individuals to store, send and spend their digital assets, to building the infrastructure to give businesses the opportunity to accept digital asset payments from their customers. The integration begins in Argentina with plans to expand across Brazil, Mexico, Colombia, Chile, Peru, Uruguay and Ecuador.

“Exodus was built to give people a better experience using their money, with more control and less friction,” said JP Richardson, CEO and Co-founder of Exodus. “Exodus Checkout extends that to everyday commerce by embedding stablecoin payments into experiences people already enjoy. Launching with DGO shows how digital dollars can become everyday money.”

Dollar stablecoins already have seen growing adoption across Latin America, particularly in markets where consumers face currency volatility. Exodus Checkout makes it simple for customers to send these dollar stablecoins directly from their wallet.

“Our job is to keep making DGO simpler and more relevant to how people across Latin America live today,” said Federico Suarez, Director of OTT Platform Marketing at Waiken ILW. “As the way consumers manage and spend money evolves, the payment experience should evolve with it. Adding stablecoin payments gives customers another way to subscribe to the entertainment they love without changing the experience they already know.”

At DGO checkout, eligible customers can select stablecoins as their payment method and initiate transactions from their wallet. Exodus Checkout supports one-time and recurring stablecoin payments.

About Exodus
Founded in 2015, Exodus Movement, Inc. (NYSE American: EXOD) is pioneering self-custodial finance by giving people the tools to earn rewards, spend, manage, and swap digital assets across borders, all without giving up control. Exodus serves millions of users through its products built on a simple principle: your money should be yours.

Exodus also powers crypto infrastructure and card/payment services for enterprise platforms serving millions of users through its enterprise product suite. Headquartered in Omaha, Nebraska, Exodus is financial software where ownership is the default. For more information, visit exodus.com.

Investor Contact
investors@exodus.com

Media Contact
Aubrey Strobel/Elena Nisonoff, Halcyon Communications
exodus@halcyonpr.xyz

Disclosure Information
Exodus uses the following as means of disclosing material nonpublic information and for complying with disclosure obligations under Regulation FD: websites exodus.com/investors and exodus.com; press releases; public videos, calls, and webcasts; and social media: X (@exodus and JP Richardson’s feed @jprichardson), Facebook, LinkedIn, and YouTube.

About DGO
DGO is the live TV and streaming platform of Waiken ILW. Subscribers enjoy access to live channels and a wide selection of on-demand content, including series, movies, and documentaries, available anytime and anywhere on smartphones, tablets, laptops, computers, and Smart TVs. The service is available in Argentina, Chile, Colombia, Ecuador, Mexico, Peru, and Uruguay. Customers can also enhance their subscriptions through content partnerships with Amazon Prime, Disney+, HBO Max, and Paramount+. For more information, visit www.directvgo.com.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the planned expansion of Exodus Checkout into additional markets across Latin America; the scope, functionality, and availability of Exodus Checkout, including support for one-time and recurring stablecoin payments; the continued development and adoption of Exodus Checkout; and the future relationship and collaboration between Exodus and DGO. All statements, other than statements of historical facts, may be forward-looking statements.

These statements are based on our current expectations and projections about future events and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements, including, among others, changes in regulatory requirements or interpretations applicable to stablecoins, digital assets, and payment services in the markets where Exodus Checkout is available; technical or operational challenges related to blockchain and payment integrations; product development and geographic expansion timelines; customer and merchant adoption; the ability to establish, maintain, and perform under relationships with third-party service providers and partners; market conditions; and other risks and uncertainties set forth in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances after the date hereof, except as required by law.

HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of September 30, 2026.

As of September 30, 2026, the Company’s net assets were $2.6 billion, and its net asset value per share was $15.42. As of September 30, 2026, the Company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 589% and the Company’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 471%.

STATEMENT OF ASSETS AND LIABILITIES SEPTEMBER 30, 2026   // (UNAUDITED)
		(in millions)
Investments		$	3,694.3
Cash and cash equivalents			8.7
Receivable for securities sold			13.0
Accrued income			1.9
Other assets			0.5
Total assets			3,718.4
Credit facility			112.0
Notes			450.0
Unamortized notes issuance costs			(3.1	)
Preferred stock			141.6
Unamortized preferred stock issuance costs			(0.7	)
Total leverage			699.8
Other liabilities			9.7
Current tax liability, net			14.3
Deferred tax liability, net			386.5
Total liabilities			410.5
Net assets		$	2,608.1

The Company had 169,126,038 common shares outstanding as of September 30, 2026.

Long-term investments consisted of Midstream Energy Companies (98%), Power Infrastructure Companies (1%) and Other (1%).

The Company’s ten largest holdings by issuer at September 30, 2026 were:

			Amount (in millions)			% Long-Term Investments
1.	Energy Transfer LP (Midstream Energy Company)		$406.1			11.0	%
2.	Cheniere Energy, Inc. (Midstream Energy Company)			385.7		10.4	%
3.	Enterprise Products Partners L.P. (Midstream Energy Company)			362.4		9.8	%
4.	The Williams Companies, Inc. (Midstream Energy Company)			356.3		9.6	%
5.	MPLX LP (Midstream Energy Company)			262.9		7.1	%
6.	Targa Resources Corp. (Midstream Energy Company)			247.8		6.7	%
7.	ONEOK, Inc. (Midstream Energy Company)			241.2		6.5	%
8.	Kinder Morgan, Inc. (Midstream Energy Company)			194.9		5.3	%
9.	TC Energy Corporation (Midstream Energy Company)			150.5		4.1	%
10.	Western Midstream Partners, LP (Midstream Energy Company)			144.1		3.9	%

Portfolio holdings are subject to change without notice. The mention of specific securities is not a recommendation or solicitation for any person to buy, sell or hold any particular security. You can obtain a complete listing of holdings by viewing the Company’s most recent quarterly or annual report.

Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN) is a non-diversified, closed-end management investment company registered under the Investment Company Act of 1940, as amended, whose common stock trades on the NYSE. The Company’s investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to stockholders. KYN intends to achieve this objective by investing at least 80% of its total assets in securities of Energy Infrastructure Companies. See Glossary of Key Terms in the Company’s most recent quarterly or annual report for a description of these investment categories and the meaning of capitalized terms.

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of any securities in any jurisdiction in which such offer or sale is not permitted. Nothing contained in this press release is intended to recommend any investment policy or investment strategy or consider any investor’s specific objectives or circumstances. Before investing, please consult with your investment, tax, or legal adviser regarding your individual circumstances.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This communication contains statements reflecting assumptions, expectations, projections, intentions, or beliefs about future events. These and other statements not relating strictly to historical or current facts constitute forward-looking statements as defined under the U.S. federal securities laws. Forward-looking statements involve a variety of risks and uncertainties. Risks include, but are not limited to, changes in economic and political conditions; regulatory and legal changes; energy industry risk; leverage risk; valuation risk; interest rate risk; tax risk; and other risks discussed in detail in the Company’s filings with the SEC, available at www.kaynefunds.com or www.sec.gov. Actual results or events could differ materially from these statements or our present expectations or projections. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. Kayne Anderson undertakes no obligation to publicly update or revise any forward-looking statements made herein. There is no assurance that the Company’s investment objectives will be attained.

Contact investor relations at 877-657-3863 or cef@kayneanderson.com.